Clinical Study
The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1)
Table 2
Association between ACR20 response and biomarker change at Week 16.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NS: not significant. ORs, CIs, and values were calculated from a logistic regression model with percent change from baseline biomarker value at Week 16 (LOCF) as a covariate. At Week 16 (LOCF) for the biomarkers with a significantly () different percent change from baseline in the between-treatment comparisons (apremilast 20 mg BID versus placebo or apremilast 30 mg BID versus placebo), the ACR20 (nonresponder imputation) and ACR20 (LOCF) datasets were identical. ‡P values were calculated from a logistic regression model with treatment as a factor, percent change from baseline biomarker value at Week 16 (LOCF) as a covariate, and interaction of treatment and percent change from baseline value at Week 16 (LOCF). |